Written by According to Fortune Business Insights, the global follicle stimulating hormones market size was valued at USD 3.96 billion in 2025. The market is projected to grow from USD 4.21 billion in 2026 to USD 6.90 billion by 2034, exhibiting a CAGR of 6.37% during the forecast period from 2026 to 2034. North America dominated the market, accounting for a 31.81% market share in 2025.
Market Overview
The global follicle stimulating hormones market includes recombinant FSH, urinary-derived FSH, and FSH combination products. These therapies are used across controlled ovarian stimulation for IVF/ICSI, ovulation induction, male infertility or spermatogenesis induction, and fertility preservation.
The market is supported by the substantial global burden of infertility. According to the source, around 17.5% of adults worldwide, or approximately one in six people, experience infertility during their lifetime. This creates a significant long-term need for fertility treatments and related hormonal therapies.
Recombinant FSH products are increasingly adopted because of standardized dosing, self-administration options, and availability through pre-filled injection pens. Meanwhile, pharmaceutical companies are investing in personalized ovarian-stimulation protocols, biosimilars, and advanced formulations to expand treatment options.
For detailed market insights: https://www.fortunebusinessinsights.com/follicle-stimulating-hormones-market-111656
Market Trends
Increasing Strategic Partnerships for Fertility Hormone Products
Increasing licensing, supply, development, and commercialization partnerships are a prominent trend in the follicle stimulating hormones market. Established pharmaceutical companies are collaborating with fertility-drug developers to utilize commercial infrastructure, reduce market-entry requirements, and accelerate product availability.
These partnerships are particularly relevant for recombinant and long-acting FSH products, which require specialized manufacturing, clinical validation, and regulatory approvals. For example, in September 2024, Organon collaborated with Shanghai Bao Pharmaceutical and Suzhou Centergene Pharmaceuticals for SJ02, an investigational long-acting FSH product, obtaining commercialization rights for mainland China.
Market Drivers
Expansion of IVF, ICSI, and ART Treatment Volumes
The increasing number of IVF, ICSI, and other ART procedures is a major factor driving follicle stimulating hormones market growth. FSH-based medicines are administered during controlled ovarian stimulation to encourage the development of multiple ovarian follicles and facilitate the collection of sufficient eggs for fertilization.
As fertility clinics expand their capacity and patients undergo repeated treatment cycles, demand for recombinant FSH, urinary-derived FSH, and combination products is expected to increase. The source notes that in the U.K., 64,000 patients underwent more than 100,000 treatments and freezing cycles at HFEA-licensed clinics in 2024, highlighting sustained ART utilization.
Other factors supporting growth include rising infertility prevalence, delayed parenthood, expansion of fertility clinics and ART infrastructure, growing adoption of recombinant FSH, patient-friendly delivery systems, and geographic expansion of biosimilar and lower-cost FSH products.
Market Segmentation
By Type
Based on type, the market is segmented into recombinant FSH, urinary-derived FSH, FSH combination products, and others. The recombinant FSH segment is expected to lead the market. Its adoption is supported by standardized dosing and convenient administration options.
By Product
The market is divided into follitropin alfa, follitropin beta, urofollitropin, menotropins/hMG, corifollitropin alfa, and others. Menotropins/hMG held the largest market share in 2025, supported by its established use in controlled ovarian stimulation and combined FSH and luteinizing hormone activity.
By Application
Applications include controlled ovarian stimulation for IVF/ICSI, ovulation induction, male infertility/spermatogenesis induction, fertility preservation, and others.
By Patient Group
Based on patient group, the market is categorized into male and female patients.
By Route of Administration
The market is segmented into subcutaneous and intramuscular administration.
By Distribution Channel
Distribution channels include hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.
Key Players
The follicle stimulating hormones market is moderately consolidated, with several established pharmaceutical companies maintaining strong positions through broad fertility-drug portfolios and geographic distribution capabilities.
Key companies include Merck KGaA, Ferring, Organon & Co., Chemical Works of Gedeon Richter Plc., IBSA Institut Biochimique SA, Theramex, Qilu Pharmaceutical Co., Ltd., Intas Pharmaceuticals Ltd., Gufic Biosciences Limited, and ASKA Pharmaceutical Co., Ltd.
These companies are focusing on portfolio expansion, recombinant and urinary-derived gonadotropins, patient-friendly delivery systems, personalized FSH dosing, long-acting formulations, biosimilars, strategic licensing, and acquisitions.
Regional Analysis
North America held the leading position in the global market in 2025, with a market value of USD 1.26 billion and a 31.81% global share. High IVF/ICSI treatment volumes, advanced healthcare infrastructure, and growing insurance and employer-supported fertility benefits contribute to regional growth. The U.S. market is estimated at approximately USD 1.22 billion in 2026.
Europe is projected to register a 5.70% CAGR during the forecast period and reach USD 1.42 billion in 2026. Increasing ART procedures, public fertility programs, and improving reimbursement support demand.
Asia Pacific accounted for the third-largest market share in 2025 and is estimated to reach USD 1.08 billion in 2026. Delayed parenthood, declining fertility rates, increasing infertility awareness, private fertility-clinic expansion, and government initiatives are supporting regional growth. China, Japan, and India are important markets in the region.
Latin America is expected to witness significant growth, with the regional market projected to reach USD 0.16 billion in 2026. Meanwhile, the Middle East & Africa market is supported by increasing access to assisted reproduction, with the GCC expected to reach USD 0.06 billion in 2026.
Competitive Landscape
Companies operating in the follicle stimulating hormones market are emphasizing strategic collaborations, product launches, biosimilar development, acquisitions, and regulatory approvals. In March 2026, Gedeon Richter acquired a reproductive-health discovery portfolio from Celmatix that included an oral FSH receptor agonist.
Other developments include partnerships for follitropin alfa biosimilars and long-acting recombinant FSH products, while regulatory approvals for recombinant human FSH injections are supporting the expansion of treatment options. These activities demonstrate the industry’s focus on improving accessibility, treatment convenience, and product differentiation.
Future Outlook
The future outlook for the follicle stimulating hormones market remains positive as infertility treatment demand and ART utilization continue to expand. Increasing fertility awareness, expanding clinic networks, delayed parenthood, and broader access to reproductive technologies are expected to sustain demand.
Biosimilar and generic FSH products could create additional opportunities by lowering treatment costs and improving access in high-cost and underserved markets. At the same time, long-acting formulations, personalized ovarian-stimulation approaches, patient-friendly delivery systems, and strategic partnerships are likely to influence future product development.
However, high out-of-pocket treatment costs, uneven reimbursement, safety considerations, complex biologic manufacturing, and shortages of fertility specialists and ART infrastructure may limit market expansion in certain regions.
Conclusion
The global follicle stimulating hormones market is positioned for steady growth through 2034, supported by increasing infertility treatment demand, rising IVF and ICSI volumes, and expanding fertility-care infrastructure. With the market projected to increase from USD 4.21 billion in 2026 to USD 6.90 billion by 2034, pharmaceutical companies are increasingly focusing on recombinant FSH, biosimilars, long-acting formulations, and patient-centric delivery solutions. Strategic partnerships and geographic expansion are expected to remain important competitive strategies as companies seek to improve access to fertility treatments worldwide.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/follicle-stimulating-hormones-market-111656
Frequently Asked Questions
1. What is the current size of the follicle stimulating hormones market?
According to Fortune Business Insights, the global follicle stimulating hormones market was valued at USD 3.96 billion in 2025 and is projected to reach USD 6.90 billion by 2034.
2. What will be the value of the follicle stimulating hormones market by 2034?
The global follicle stimulating hormones market is projected to reach USD 6.90 billion by 2034, increasing from USD 4.21 billion in 2026.
3. What is the CAGR of the follicle stimulating hormones market?
The market is expected to expand at a CAGR of 6.37% from 2026 to 2034.
4. Which segment is expected to lead the follicle stimulating hormones market?
The recombinant FSH type segment is expected to lead the market, supported by standardized dosing, self-administration options, and patient-friendly delivery systems. By product, menotropins/hMG held the largest share in 2025.
5. Which region dominated the follicle stimulating hormones market in 2025?
North America dominated the global market in 2025 with a 31.81% market share and a market value of USD 1.26 billion.
What’s Driving Japan’s Market? Discover the Latest Follicle Stimulating Hormones Market Insights